

Supplementary File 1 STROBE Statement

Supplementary The PRISMA Statement			Page No
	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	pg 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	pg1-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	pg 3-6
Objectives	3	State specific objectives, including any prespecified hypotheses	pg6 lines 112-117
Methods			
Study design	4	Present key elements of study design early in the paper	pg6 lines 121-123
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	pg6-7 lines 126-148
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	pg7 lines 135-141
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	pg7-13 pg14-15
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	pg7-13
Bias	9	Describe any efforts to address potential sources of bias	pg14-15 lines 287-319
Study size	10	Explain how the study size was arrived at	pg13 lines 274-282
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	pg14-15
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	pg14-15 lines 291-297
		(b) Describe any methods used to examine subgroups and interactions	pg13-14
		(c) Explain how missing data were addressed	pg13 lines 274-282
		(d) If applicable, describe analytical methods taking account of sampling strategy	pg13 lines 274-282
		(e) Describe any sensitivity analyses	Not
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	pg15 lines 223-326

		(b) Give reasons for non-participation at each stage	pg13 lines 274-282
		(c) Consider use of a flow diagram	Not
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	pg15 lines 223-326
		(b) Indicate number of participants with missing data for each variable of interest	pg13 lines 274-282
Outcome data	15*	Report numbers of outcome events or summary measures	pg17 lines 336-344
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	pg18-19 lines 345-392
		(b) Report category boundaries when continuous variables were categorized	pg18-19 lines 345-392
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not
Discussion			
Key results	18	Summarise key results with reference to study objectives	pg20-21 lines 395-401
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	pg27-28 lines 547-564
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	pg21-27
Generalisability	21	Discuss the generalisability (external validity) of the study results	pg27-28 lines 547-564
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	pg30 lines 601-602

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.